A., O., & University, M. (2023). Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results.
Chicago Style CitationA., Oey, and Mahidol University. Lumicitabine, an Orally Administered Nucleoside Analog, in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection: Safety, Efficacy, and Pharmacokinetic Results. 2023.
MLA CitationA., Oey, and Mahidol University. Lumicitabine, an Orally Administered Nucleoside Analog, in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection: Safety, Efficacy, and Pharmacokinetic Results. 2023.
Warning: These citations may not always be 100% accurate.